NEW YORK, Nov. 8, 2017 /PRNewswire/ -- Kerrisdale Capital, a private investment manager, has published a negative report explaining its short position in Prothena Corporation PLC (PRTA), a $2.4 billion development-stage biotechnology company whose valuation is primarily based on lead drug candidate NEOD001, an antibody currently in trials to treat AL amyloidosis. Prothena's stock price has increased over 700% since its spin-off from Elan in 2012 despite no evidence that its principal asset NEOD001 works. Kerrisdale believes that NEOD001 is a poorly-understood drug that will fail its Phase 2b and Phase 3 trials.
The full report can be found at http://kerr.co/prta.
Kerrisdale has a short position in Prothena Corporation PLC and stands to benefit if its share price falls.
Conference Call ScheduleKerrisdale will host a conference call on Wednesday, November 8 at 10:30am ET to discuss the Prothena report.
To participate in the conference call, dial 888-567-1602 (US and Canada) or 404-267-0373 (international) and reference the Kerrisdale Capital call.
About Kerrisdale CapitalKerrisdale Capital Management, LLC, is a fundamentally-oriented investment manager that focuses on long-term value investments and event-driven special situations.
ContactAgnes CaoKerrisdale Capital [email protected] 212-257-4385
Kerrisdale Capital Management, LLC is a member of the Financial Industry Regulatory Authority, CRD number 160804.
Advertisement
The full report can be found at http://kerr.co/prta.
Kerrisdale has a short position in Prothena Corporation PLC and stands to benefit if its share price falls.
Advertisement
Conference Call ScheduleKerrisdale will host a conference call on Wednesday, November 8 at 10:30am ET to discuss the Prothena report.
To participate in the conference call, dial 888-567-1602 (US and Canada) or 404-267-0373 (international) and reference the Kerrisdale Capital call.
About Kerrisdale CapitalKerrisdale Capital Management, LLC, is a fundamentally-oriented investment manager that focuses on long-term value investments and event-driven special situations.
ContactAgnes CaoKerrisdale Capital [email protected] 212-257-4385
Kerrisdale Capital Management, LLC is a member of the Financial Industry Regulatory Authority, CRD number 160804.
View original content:http://www.prnewswire.com/news-releases/kerrisdale-capital-issues-negative-report-on-prothena-corporation-plc-and-announces-conference-call-schedule-300551842.html
SOURCE Kerrisdale Capital Management, LLC